SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 9,424.90 |
| Enterprise Value ($M) | 7,801.90 |
| Book Value ($M) | 10,066.00 |
| Book Value / Share | 26.03 |
| Price / Book | 0.94 |
| NCAV ($M) | 4,128.00 |
| NCAV / Share | 10.67 |
| Price / NCAV | 2.28 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.31 |
| Return on Assets (ROA) | -0.20 |
| Return on Equity (ROE) | -0.26 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 4.14 |
| Current Ratio | 4.22 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 6,766.00 |
| Assets | 12,704.00 |
| Liabilities | 2,638.00 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 3,236.00 |
| Operating Income | -3,945.00 |
| Net Income | -3,561.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -3,004.00 |
| Cash from Investing | 1,949.00 |
| Cash from Financing | 56.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Baillie Gifford & Co | 6.50 | -35.85 | |
| 13G/A | Vanguard Group Inc | 10.20 | 15.13 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 2,015,787 | 8,726,414 | 23.10 | |
| 1,944,466 | 9,160,912 | 21.23 | |
| 6,038,316 | 21,495,550 | 28.09 | |
| 1,627,281 | 6,440,302 | 25.27 | |
(click for more detail) |
|||
Financial data and stock pages provided by
Fintel.io